Cytosorbents Corp (NASDAQ:CTSO) released its earnings results on Monday. The medical research company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.06. The company had revenue of $3.11 million during the quarter, compared to the consensus estimate of $2.99 million. Cytosorbents Corp had a negative return on equity of 193.13% and a negative net margin of 120.04%.
A number of institutional investors have recently bought and sold shares of CTSO. Vanguard Group Inc. raised its position in Cytosorbents Corp by 3.9% in the first quarter. Vanguard Group Inc. now owns 567,116 shares of the medical research company’s stock valued at $2,552,000 after buying an additional 21,312 shares during the period. Skylands Capital LLC raised its position in Cytosorbents Corp by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock valued at $1,425,000 after buying an additional 293,600 shares during the period. Sabby Management LLC bought a new position in Cytosorbents Corp during the first quarter valued at $990,000. Geode Capital Management LLC raised its position in Cytosorbents Corp by 0.5% in the first quarter. Geode Capital Management LLC now owns 126,883 shares of the medical research company’s stock worth $570,000 after buying an additional 606 shares during the last quarter. Finally, Cowen Group Inc. acquired a new position in Cytosorbents Corp during the first quarter worth approximately $248,000. Institutional investors own 6.07% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.chaffeybreeze.com/2017/05/20/cytosorbents-corp-ctso-releases-earnings-results-beats-expectations-by-0-06-eps-updated.html.
Several equities analysts have weighed in on the company. B. Riley reaffirmed a “buy” rating and issued a $11.25 target price on shares of Cytosorbents Corp in a research report on Tuesday, April 11th. Maxim Group set a $10.00 price objective on Cytosorbents Corp and gave the company a “buy” rating in a research note on Saturday, May 6th. Finally, Aegis reiterated a “buy” rating on shares of Cytosorbents Corp in a research note on Tuesday, March 7th. Five investment analysts have rated the stock with a buy rating, Cytosorbents Corp currently has an average rating of “Buy” and a consensus price target of $13.45.
Cytosorbents Corp Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.